Skip to main content
SpringerLink
Log in

Oncolytic viruses for treatment of malignant brain tumours

  • Conference paper
Local Therapies for Glioma Present Status and Future Developments

Part of the book series: Acta Neurochirurgica Supplements ((NEUROCHIRURGICA,volume 88))

  • 240 Accesses

Abstract

Wild type viruses have been known for decades for their capability to destroy malignant tumour cells upon infection and intracellular replication. Genetic engineering of such viruses was, however, only recently done in an attempt to improve their utility as biological anticancer agents. Wild type or recombinant viruses able to selectively destroy tumour cells while sparing normal tissue are known as oncolytic viruses. Most oncolytic viruses currently investigated in clinical trials are derived from adenovirus (AV) or herpes simplex virus type 1 (HSV1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Advani SJ, Sibley GS, Song PY, Hallahan DE, Kataoka Y, Roizman B, Weichselbaum RR (1998) Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther 5: 160–165

    Article  PubMed  CAS  Google Scholar 

  2. Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA (1999) Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 59: 3861–3865

    PubMed  CAS  Google Scholar 

  3. Andreansky S, He B, van Cott J, McGhee J, Markert JM, Gillespie GY, Roizman B, Whitley RJ (1998) Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 5: 121–130

    Article  PubMed  CAS  Google Scholar 

  4. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B, Whitley RJ (1997) Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 57: 1502–1509

    PubMed  CAS  Google Scholar 

  5. Babiss LE, Ginsberg HS, Darnell JE Jr (1985) Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport. Mol Cell Biol 5: 2552–2558

    CAS  Google Scholar 

  6. Balague C, Noya F, Alemany R, Chow LT, Curiel DT (2001) Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes. J Virol 75: 7602–7611

    Article  PubMed  CAS  Google Scholar 

  7. Besnard F, Brenner M, Nakatani Y, Chao R, Purohit HJ, Freese E (1991) Multiple interacting sites regulate astrocytespecific transcription of the human gene for glial fibrillary acidic protein. J Biol Chem 266: 18877–18883

    PubMed  CAS  Google Scholar 

  8. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373–376

    Article  PubMed  CAS  Google Scholar 

  9. Boviatsis EJ, Park JS, Sena-Esteves M, Kramm CM, Chase M, Efird JT, Wei MX, Breakefield XO, Chiocca EA (1994) Longterm survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 54: 5745–5751

    PubMed  CAS  Google Scholar 

  10. Chahlavi A, Todo T, Martuza RL, Rabkin SD (1999) Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1: 162–169

    Article  PubMed  CAS  Google Scholar 

  11. Chase M, Chung RY, Chiocca EA (1998) An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 16: 444–448

    Article  PubMed  CAS  Google Scholar 

  12. Chen Y, Yu DC, Charlton D, Henderson DR (2000) Preexistent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum Gene Ther 11: 1553–1567

    Article  PubMed  CAS  Google Scholar 

  13. Chiocca EA (2002) Oncolytic viruses. Nat Cancer Rev 2: 938–951

    Article  Google Scholar 

  14. Christofori G, Hanahan D (1994) Molecular dissection of multistage tumorigenesis in transgenic mice. Semin Cancer Biol 5: 3–12

    PubMed  CAS  Google Scholar 

  15. Chung SM, Advani SJ, Bradley JD, Kataoka Y, Vashistha K, Yan SY, Markert JM, Gillespie GY, Whitley RJ, Roizman B, Weichselbaum RR (2002) The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther 9: 75–80

    Article  PubMed  CAS  Google Scholar 

  16. Coffey MC, Strong JE, Forsyth PA, Lee PW (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332–1334

    Article  PubMed  CAS  Google Scholar 

  17. De Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW (1998) ElA signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 12: 2434–2442

    Article  PubMed  Google Scholar 

  18. Deb A, Hague SJ, Mogensen T, Silverman RH, Williams BR (2001) RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT I-independent pathway. J Immunol 166: 6170–6180

    PubMed  CAS  Google Scholar 

  19. Debbas M, White E (1993) Wild-type p53 mediates apoptosis by El A, which is inhibited by E1B. Genes Dev 7: 546–554

    Article  PubMed  CAS  Google Scholar 

  20. DeWeese TL, Van der PH, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG, Simons JW (2001) A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61: 7464–7472

    PubMed  CAS  Google Scholar 

  21. Dirven C, Van Beusechem V, Lamfers M, Grill J, Gerritsen W, Vandertop W (2002) Oncolytic adenoviruses for treatment of brain tumours. Expert Opin Biol Ther 2: 943–952

    Article  PubMed  CAS  Google Scholar 

  22. Farassati F, Yang AD, Lee PW (2001) Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 3: 745–750

    Article  PubMed  CAS  Google Scholar 

  23. Flint J, Shenk T (1997) Viral transactivating proteins. Annu Rev Genet 31: 177–212

    Article  PubMed  CAS  Google Scholar 

  24. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH (1998) A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 9: 1323–1333

    Article  PubMed  CAS  Google Scholar 

  25. Fuxe J, Liu L, Malin S, Philipson L, Collins VP, Pettersson RF (2003) Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. Int J Cancer 103: 723–729

    Article  PubMed  CAS  Google Scholar 

  26. Ganly I, Kim D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, Von Hoff DD, Kaye SB, Eckhardt SG (2000) A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6: 798–806

    PubMed  CAS  Google Scholar 

  27. Goldstein DJ, Weller SK (1988) Factor(s) present in herpes simplex virus type I-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 166: 41–51

    Article  PubMed  CAS  Google Scholar 

  28. Goodrum FD, Ornelles DA (1998) p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 72: 9479–9490

    PubMed  CAS  Google Scholar 

  29. Haisma HJ, Grill J, Curiel DT, Hoogeland S, van Beusechem VW, Pinedo HM, Gerritsen WR (2000) Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther 7: 901–904

    Article  PubMed  CAS  Google Scholar 

  30. Harada JN, Berk AJ (1999) p53-Independent and -dependent requirements for E1B–55K in adenovirus type 5 replication. J Virol 73: 1B–55K

    PubMed  CAS  Google Scholar 

  31. Harrison D, Sauthoff H, Heitner S, Jagirdar J, Rom WN, Hay JG (2001) Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved - deletion of the viral Elb-19-kD gene increases the viral oncolytic effect. Hum Gene Ther 12: 1323–1332

    Article  PubMed  CAS  Google Scholar 

  32. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kirn D (2000) An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 6: 1134–1139

    Article  PubMed  CAS  Google Scholar 

  33. Heise C, Kirn DH (2000) Replication-selective adenoviruses as oncolytic agents. J Clin Invest 105: 847–851

    Article  PubMed  CAS  Google Scholar 

  34. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH (1997) ONYX-015, an El B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3: 639–645

    Article  PubMed  CAS  Google Scholar 

  35. Heise CC, Williams A, Olesch J, Kirn DH (1999) Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther 6: 499–504

    Article  PubMed  CAS  Google Scholar 

  36. Henson J, Saffer J, Furneaux H (1992) The transcription factor Spl binds to the JC virus promoter and is selectively expressed in glial cells in human brain. Ann Neurol 32: 72–77

    Article  PubMed  CAS  Google Scholar 

  37. Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, Toda M, Newsome JT, Platenberg RC, Manz HJ, Rabkin SD (1999) Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 73: 6319–6326

    PubMed  CAS  Google Scholar 

  38. Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, Harsh GR, Louis DN, Bartus RT, Hochberg FH, Chiocca EA (1999) Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 5: 881–887

    Article  PubMed  CAS  Google Scholar 

  39. Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M, Hermiston T, Giedlin M, McCormick F, Fattaey A (2002) Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 1: 325–337

    Article  PubMed  CAS  Google Scholar 

  40. Kao CC, Yew PR, Berk AJ (1990) Domains required for in vitro association between the cellular p53 and the adenovirus 2 ElB 55K proteins. Virology 179: 806–814

    Article  PubMed  CAS  Google Scholar 

  41. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kirn DH (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879–885

    Article  PubMed  CAS  Google Scholar 

  42. Kirn DH (2000) Replication-selective microbiological agents: fighting cancer with targeted germ warfare. J Clin Invest 105: 837–839

    Article  PubMed  CAS  Google Scholar 

  43. Kramm CM, Sena-Esteves M, Barnett FH, Rainov NG, Schuback DE, Yu JS, Pechan PA, Paulus W, Chiocca EA, Breakefield XO (1995) Gene therapy for brain tumors. Brain Pathol 5: 345–381

    Article  PubMed  CAS  Google Scholar 

  44. Lane DP (1999) Exploiting the p53 pathway for cancer diagnosis and therapy. Br J Cancer 80 [Suppl] 1: 1–5

    Google Scholar 

  45. Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP, Wang Z, Hsieh JT (1999) Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 59: 325–330

    PubMed  CAS  Google Scholar 

  46. Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR (2001) A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 61: 6428–6436

    PubMed  CAS  Google Scholar 

  47. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM (1997) Binding and modulation of p53 by p300/CBP co-activators. Nature 387: 823–827

    Article  PubMed  CAS  Google Scholar 

  48. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, Love CA, Coffin RS (2003) ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 10: 292–303

    Article  PubMed  CAS  Google Scholar 

  49. Lorence RM, Reichard KW, Katubig BB, Reyes HM, Phuangsab A, Mitchell BR, Cascino CJ, Walter RJ, Peeples ME (1994) Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst 86: 1228–1233

    Article  PubMed  CAS  Google Scholar 

  50. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867–874

    Article  PubMed  CAS  Google Scholar 

  51. Markert JM, Parker JN, Gillespie GY, Whitley RJ (2001) Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes 8: 17–22

    PubMed  CAS  Google Scholar 

  52. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854–856

    Article  PubMed  CAS  Google Scholar 

  53. McCormick F (2000) ONYX-015 selectivity and the p14ARF pathway. Oncogene 19: 6670–6672

    Article  PubMed  CAS  Google Scholar 

  54. Mineta T, Rabkin SD, Martuza RL (1994) Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 54: 3963–3966

    PubMed  CAS  Google Scholar 

  55. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1: 938–943

    Article  PubMed  CAS  Google Scholar 

  56. Miyao Y, Shimizu K, Tamura M, Akita H, Ikeda K, Mabuchi E, Kishima H, Hayakawa T, Ikenaka K (1997) Usefulness of a mouse myelin basic protein promoter for gene therapy of malignant glioma: myelin basic protein promoter is strongly active in human malignant glioma cells. Jpn J Cancer Res 88: 678–686

    PubMed  CAS  Google Scholar 

  57. Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46: 5276–5281

    PubMed  CAS  Google Scholar 

  58. Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, Kirn D (2001) Safety and feasibility of injection with an E1 B55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 8: 308–315

    Article  PubMed  CAS  Google Scholar 

  59. Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS (2001) Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 61: 8743–8750

    PubMed  CAS  Google Scholar 

  60. Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, Netto G, Tong A, Randlev B, Olson S, Kirn D (2001) Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 8: 746–759.

    Article  PubMed  CAS  Google Scholar 

  61. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, Kirn D (2000) Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 60: 6359–6366

    PubMed  CAS  Google Scholar 

  62. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landers S, Blackburn A, Romel L, Randlev B, Kaye S, Kirn D (2001) Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19: 289–298

    CAS  Google Scholar 

  63. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fos-sella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL (2000) Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 18: 609–622

    PubMed  CAS  Google Scholar 

  64. Papanastassiou V, Rampling R, Fraser M, Petty R, Hadley D, Nicoll J, Harland J, Mabbs R, Brown M (2002) The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 9: 398–406

    Article  PubMed  CAS  Google Scholar 

  65. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O’Neil JD, Groene WS, Roberts MS, Rabin H, Bamat MK, Lorence RM (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20: 2251–2266

    Article  PubMed  CAS  Google Scholar 

  66. Rainov NG, Kramm CM (2001) Vector delivery methods and targeting strategies for gene therapy of brain tumors. Curr Gene Ther 1: 367–383

    Article  PubMed  CAS  Google Scholar 

  67. Rainov NG, Kramm CM, Banning U, Riemann D, Holzhausen HJ, Heidecke V, Burger KJ, Burkert W, Korholz D (2000) Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme. Gene Ther 7: 1853–1858

    Article  PubMed  CAS  Google Scholar 

  68. Rainov NG (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11: 2389–2401

    Article  PubMed  CAS  Google Scholar 

  69. Raj K, Ogston P, Beard P (2001) Virus-mediated killing of cells that lack p53 activity. Nature 412: 914–917

    Article  PubMed  CAS  Google Scholar 

  70. Ramachandra M, Rahman A, Zou A, Vaillancourt M, Howe JA, Antelman D, Sugarman B, Demers GW, Engler H, Johnson D, Shabram P (2001) Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol 19: 1035–1041

    Article  PubMed  CAS  Google Scholar 

  71. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, Petty R, MacLean A, Harland J, McKie E, Mabbs R, Brown M (2000) Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7: 859–866

    Article  PubMed  CAS  Google Scholar 

  72. Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB, Reyes HM, Greager JA (1992) Newcastle disease virus selectively kills human tumor cells. J Surg Res 52: 448–453

    Article  PubMed  CAS  Google Scholar 

  73. Ries S, Korn WM (2002) ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer 86: 5–11

    Article  PubMed  CAS  Google Scholar 

  74. Ries SJ, Brandts CH, Chung AS, Biederer CH, Hann BC, Lipner EM, McCormick F, Korn WM (2000) Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015). Nat Med 6: 1128–1133

    Article  PubMed  CAS  Google Scholar 

  75. Rogulski KR, Freytag SO, Zhang K, Gilbert JD, Paielli DL, Kim JH, Heise CC, Kirn DH (2000) In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 60: 1193–1196

    PubMed  CAS  Google Scholar 

  76. Samoto K, Ehtesham M, Perng GC Hashizume K, Wechsler SL, Nesburn AB, Black KL, Yu JS (2002) A herpes simplex virus type 1 mutant with gamma 34.5 and LAT deletions effectively oncolyses human U87 glioblastomas in nude mice. Neurosurgery 50: 599–605

    PubMed  Google Scholar 

  77. Smith R, Huebner RJ, Rowe WP, Schatten WE, Thomas LB (1956) Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9: 1211–1218

    Article  PubMed  Google Scholar 

  78. Spear MA, Sun F, Eling DJ, Gilpin E, Kipps TJ, Chiocca EA, Bouvet M (2000) Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductasedefective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther 7: 1051–1059

    Article  PubMed  CAS  Google Scholar 

  79. Stanziale SF, Petrowsky H, Joe JK, Roberts GD, Zager JS, Gusani NJ, Ben Porat L, Gonen M, Fong Y (2002) Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery 132: 353–359

    Article  PubMed  Google Scholar 

  80. Steele RJ, Thompson AM, Hall PA, Lane DP (1998) The p53 tumour suppressor gene. Br J Surg 85: 1460–1467

    Article  PubMed  CAS  Google Scholar 

  81. Terry-Allison T, Montgomery RI, Whitbeck JC, Xu R, Cohen GH, Eisenberg RJ, Spear PG (1998) HveA (herpesvirus entry mediator A), a coreceptor for herpes simplex virus entry, also participates in virus-induced cell fusion. J Virol 72: 5802–5810

    PubMed  CAS  Google Scholar 

  82. Timiryasova TM, Li J, Chen B, Chong D, Langridge WH, Gridley DS, Fodor I (1999) Antitumor effect of vaccinia virus in glioma model. Oncol Res 11: 133–144

    PubMed  CAS  Google Scholar 

  83. Toda M, Martuza RL, Kojima H, Rabkin SD (1998) In situ cancer vaccination: an IL-12 defective vector/replicationcompetent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 160: 4457–4464

    PubMed  CAS  Google Scholar 

  84. Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB, Martuza RL (1999) Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 10: 2741–2755

    Article  PubMed  CAS  Google Scholar 

  85. Vandier D, Rixe O, Besnard F, Kim M, Rikiyama T, Goldsmith M, Brenner M, Gouyette A, Cowan KH (2000) Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. Cancer Gene Ther 7: 1120–1126

    Article  PubMed  CAS  Google Scholar 

  86. Varghese S, Rabkin SD (2002) Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 9: 967–978

    Article  PubMed  CAS  Google Scholar 

  87. Vogelstein B, Kinzler KW (1993) The multistep nature of cancer. Trends Genet 9: 138–141

    Article  PubMed  CAS  Google Scholar 

  88. Wakimoto H, Ikeda K, Abe T, Ichikawa T, Hochberg FH, Ezekowitz RA, Pasternack MS, Chiocca EA (2002) The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther 5: 275–282

    Article  PubMed  CAS  Google Scholar 

  89. Webb HE, Smith CE (1970) Viruses in the treatment of cancer. Lancet 1: 1206–1208

    Article  PubMed  CAS  Google Scholar 

  90. Whyte P, Ruley HE, Harlow E (1988) Two regions of the adenovirus early region lA proteins are required for transformation. J Virol 62: 257–265

    PubMed  CAS  Google Scholar 

  91. Wickham TJ (2000) Targeting adenovirus. Gene Ther 7: 110–114

    Article  PubMed  CAS  Google Scholar 

  92. Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Brasher PM, Shi ZQ, Johnston RN, Nishikawa S, Lee PW, Forsyth PA (2001) Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 93: 903–912

    Article  PubMed  CAS  Google Scholar 

  93. Williams BR (1999) PKR: a sentinel kinase for cellular stress. Oncogene 18: 6112–6120

    Article  PubMed  CAS  Google Scholar 

  94. Wodarz D (2001) Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res 61: 3501–3507

    PubMed  CAS  Google Scholar 

  95. Yang CT, You L, Uematsu K, Yeh CC, McCormick F, Jablons DM (2001) p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res 61: 5959–5963

    PubMed  CAS  Google Scholar 

  96. Yew PR, Berk AJ (1992) Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 357: 82–85

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurological Science, University of Liverpool, UK

    N. G. Rainov

  2. The Walton Centre for Neurology and Neurosurgery NHS Trust, Liverpool, UK

    H. Ren

Authors
  1. N. G. Rainov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Neurochirurgie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

    M. Westphal

  2. Neurochirurgische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, München, Germany

    J.-C. Tonn

  3. Department of Neurosurgery, Tel Aviv Medical Center, Tel Aviv, Israel

    Z. Ram

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag/Wien

About this paper

Cite this paper

Rainov, N.G., Ren, H. (2003). Oncolytic viruses for treatment of malignant brain tumours. In: Westphal, M., Tonn, JC., Ram, Z. (eds) Local Therapies for Glioma Present Status and Future Developments. Acta Neurochirurgica Supplements, vol 88. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6090-9_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6090-9_17

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-40355-6

  • Online ISBN: 978-3-7091-6090-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation